Colin Clyne
Associate Professor
Centre for Cancer Research
Hudson Institute of Medical Research
Australia
Biography
After graduating from Edinburgh University, UK in 1994 with a PhD in pharmacology, Dr Clyne travelled to the USA, where he completed postdoctoral training with Professor Bill Rainey at the University of Texas Southwestern Medical Centre at Dallas. With a keen interest in gene expression and cancer, he joined Hudson Institute of Medical Research in 1998, where he established the Cancer Drug Discovery Laboratory to drive research into novel endocrine therapeutic targets in breast cancer.
Research Interest
Dr Clyne’s current research interests include the pharmacology of nuclear receptors and their co-regulators, and the regulation and action of oestrogen in breast cancer.
Publications
-
Aesoy R, Clyne CD, Chand AL (2015) Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer. Frontiers in Endocrinology 6:1–11.
-
Zingue S, Nde CBM, Michel T, Ndinteh DT, Tchatchou J, Adamou M, Fernandez X, Fohouo F-NT, Clyne CD, Njamen D (2017) Ethanol-extracted Cameroonian propolis exerts estrogenic effects and alleviates hot flushes in ovariectomized Wistar rats. BMC Complementary and Alternative Medicine 17:65.
-
Coulson R, Liew SH, Connelly AA, Yee NS, Deb S, Kumar B, Vargas AC, O’Toole SA, Parslow AC, Poh A, Putoczki T, Morrow RJ, Alorro M, Lazarus KA, Yeap EFW, Walton KL, Harrison CA, Hannan NJ, George AJ, Clyne CD, Ernst M, Allen AM, Chand AL (2017) The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget 8:18640–18656.
